In FGD patients, TXNRD2 variants lead to excessive levels of mitochondrial superoxides, only partially managed by the glutathione system, thus inducing adrenal gland dysfunction; however, the exact mechanism behind TXNRD2-related adrenal damage is currently unknown [17]. Here, TXNRD2 is linked to Aarskog-Scott syndrome, X-linked.